Literature DB >> 12595459

Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1.

Alfred Cortés1, Mata Mellombo, Ivo Mueller, Ariadna Benet, John C Reeder, Robin F Anders.   

Abstract

Plasmodium falciparum apical membrane antigen 1 (AMA1) is a prime malaria vaccine candidate. Antigenic diversity within parasite populations is one of the main factors potentially limiting the efficacy of any asexual-stage vaccine, including one based on AMA1. The DNA coding for the most variable region of this antigen, domain I, was sequenced in 168 samples from the Wosera region of Papua New Guinea, including samples from symptomatic and asymptomatic infections. Neutrality tests applied to these sequences provided strong evidence of selective pressure operating on the sequence of ama1 domain I, consistent with AMA1 being a target of protective immunity. Similarly, a peculiar pattern of geographical diversity and the particular substitutions found were suggestive of strong constraints acting on the evolution of AMA1 at the population level, probably as a result of immune pressure. In addition, a strong imbalance between symptomatic and asymptomatic infections was detected in the frequency of particular residues at certain polymorphic positions, pointing to AMA1 as being one of the determinants of the morbidity associated with a particular strain. The information yielded by this study has implications for the design and assessment of AMA1-based vaccines and provides additional data supporting the importance of AMA1 as a malaria vaccine candidate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595459      PMCID: PMC148836          DOI: 10.1128/IAI.71.3.1416-1426.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Statistical method for testing the neutral mutation hypothesis by DNA polymorphism.

Authors:  F Tajima
Journal:  Genetics       Date:  1989-11       Impact factor: 4.562

2.  Statistical tests of neutrality of mutations.

Authors:  Y X Fu; W H Li
Journal:  Genetics       Date:  1993-03       Impact factor: 4.562

3.  Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites.

Authors:  D L Narum; A W Thomas
Journal:  Mol Biochem Parasitol       Date:  1994-09       Impact factor: 1.759

4.  Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species.

Authors:  T Triglia; J Healer; S R Caruana; A N Hodder; R F Anders; B S Crabb; A F Cowman
Journal:  Mol Microbiol       Date:  2000-11       Impact factor: 3.501

5.  Population structure of recrudescent Plasmodium falciparum isolates from western Uganda.

Authors:  T Jelinek; A H Kilian; A Westermeier; S Pröll; G Kabagambe; H D Nothdurft; F von Sonnenburg; T Löscher
Journal:  Trop Med Int Health       Date:  1999-07       Impact factor: 2.622

6.  Molecular characterisation of Plasmodium reichenowi apical membrane antigen-1 (AMA-1), comparison with P. falciparum AMA-1, and antibody-mediated inhibition of red cell invasion.

Authors:  C H Kocken; D L Narum1; A Massougbodji; B Ayivi; M A Dubbeld; A van der Wel; D J Conway; A Sanni; A W Thomas
Journal:  Mol Biochem Parasitol       Date:  2000-07       Impact factor: 1.759

7.  Area effects of bednet use in a malaria-endemic area in Papua New Guinea.

Authors:  J L Hii; T Smith; P Vounatsou; N Alexander; A Mai; E Ibam; M P Alpers
Journal:  Trans R Soc Trop Med Hyg       Date:  2001 Jan-Feb       Impact factor: 2.184

8.  High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1.

Authors:  A W Thomas; J F Trape; C Rogier; A Goncalves; V E Rosario; D L Narum
Journal:  Am J Trop Med Hyg       Date:  1994-12       Impact factor: 2.345

9.  Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection.

Authors:  D L Narum; S A Ogun; A W Thomas; A A Holder
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

10.  Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.

Authors:  L Rénia; I T Ling; M Marussig; F Miltgen; A A Holder; D Mazier
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

View more
  60 in total

1.  Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response.

Authors:  P V Lalitha; Lisa A Ware; Arnoldo Barbosa; Sheetij Dutta; J Kathleen Moch; J David Haynes; Bader B Fileta; Charles E White; David E Lanar
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

2.  Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.

Authors:  Karen S Harris; Christopher G Adda; Madhavi Khore; Damien R Drew; Antonina Valentini-Gatt; Freya J I Fowkes; James G Beeson; Sheetij Dutta; Robin F Anders; Michael Foley
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

3.  Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.

Authors:  Alfred Cortés; Mata Mellombo; Rosella Masciantonio; Vince J Murphy; John C Reeder; Robin F Anders
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody.

Authors:  A M Coley; K Parisi; R Masciantonio; J Hoeck; J L Casey; V J Murphy; K S Harris; A H Batchelor; R F Anders; M Foley
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

5.  Structural basis of antigenic escape of a malaria vaccine candidate.

Authors:  Sheetij Dutta; Seung Yeon Lee; Adrian H Batchelor; David E Lanar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-16       Impact factor: 11.205

Review 6.  The apicomplexan glideosome and adhesins - Structures and function.

Authors:  Lauren E Boucher; Jürgen Bosch
Journal:  J Struct Biol       Date:  2015-03-09       Impact factor: 2.867

7.  Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.

Authors:  Kazutoyo Miura; Raul Herrera; Ababacar Diouf; Hong Zhou; Jianbing Mu; Zonghui Hu; Nicholas J MacDonald; Karine Reiter; Vu Nguyen; Richard L Shimp; Kavita Singh; David L Narum; Carole A Long; Louis H Miller
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

8.  Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine.

Authors:  Amed Ouattara; Jianbing Mu; Shannon Takala-Harrison; Renion Saye; Issaka Sagara; Alassane Dicko; Amadou Niangaly; Junhui Duan; Ruth D Ellis; Louis H Miller; Xin-zhuan Su; Christopher V Plowe; Ogobara K Doumbo
Journal:  Malar J       Date:  2010-06-21       Impact factor: 2.979

9.  Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein.

Authors:  Martha Sedegah; Yohan Kim; Bjoern Peters; Shannon McGrath; Harini Ganeshan; Jennylynn Lejano; Esteban Abot; Glenna Banania; Maria Belmonte; Renato Sayo; Fouzia Farooq; Denise L Doolan; David Regis; Cindy Tamminga; Ilin Chuang; Joseph T Bruder; C Richter King; Christian F Ockenhouse; Bart Faber; Edmond Remarque; Michael R Hollingdale; Thomas L Richie; Alessandro Sette
Journal:  Malar J       Date:  2010-08-24       Impact factor: 2.979

10.  Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum.

Authors:  Alyssa E Barry; Lee Schultz; Caroline O Buckee; John C Reeder
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.